TS
The Still River Fund
Venture CapitalActiveA classic venture capital organization seeking to make investments in dynamic growing companies.
15
Investments
5
Exits
—
AUM
33.3%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for The Still River Fund.
Investment Thesis & Strategy
The Still River Fund invests in dynamic, growing companies across various stages and industries, representing a generalist approach to venture capital.
Investment Activity
Deals per year over the last 6 years
3
20164
20173
20180
20190
20202
2021Portfolio Companies
Selected investments from their portfolio of 15 companies
V
Ventyx Biosciences
Biotech · Series A, 2021
A
Apogee Therapeutics
Biotech · Series A, 2021
V
Vividion Therapeutics
Biotech · Series B, 2018
T
Terns Therapeutics
Biotech · Series A, 2018
V
Vaxcyte
Biotech · Series A, 2018
B
Black Diamond Therapeutics
Biotech · Series A, 2017
G
Gossamer Bio
Biotech · Series A, 2017
L
Lyra Therapeutics
Biotech · Series B, 2017
C
Cabaletta Bio
Biotech · Series A, 2017
R
Rani Therapeutics
Biotech · Series A, 2016
P
Pliant Therapeutics
Biotech · Series A, 2016
B
BridgeBio Pharma
Biotech · Series A, 2016
Frequently Asked Questions
The Still River Fund focuses on Series A, Series B, Series C+ stage investments.